Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neutropenic Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chemotherapy-related neutropenia (granulocytes \< 0.5 × 109/l or leukocytes \< 1 × 109/l) and fever (body temperature \> 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.

Exclusion Criteria

* prolonged fever before presenting for admission,
* antibiotics therapy in the past 72 hours,
* more than two sites of infectious focus,
* concomitant solid organ malignancy and blast in hemogram.

Minimum Eligible Age

18 Years

Maximum Eligible Age

84 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Szu-Chun Hsu, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200806051R

Identifier Type: -

Identifier Source: org_study_id